Aventa™ Genomics, LLC, a clinical laboratory deploying 3D genomics to improve patient outcomes, and a wholly-owned subsidiary of Arima Genomics, Inc., today announced that it has received a favorable final pricing determination for the 2025 Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory Fee Schedule (CLFS). The pricing determination is for the Aventa FusionPlus test, …
Aventa FusionPlus test that detects gene fusions, translocations, and rearrangements receives favorable pricing determination from CMS
Share.